Literature DB >> 26207767

Prazosin Reduces Alcohol Intake in an Animal Model of Alcohol Relapse.

Janice C Froehlich1, Brett Hausauer1, Stephen Fischer1, Bradley Wise1, Dennis D Rasmussen2.   

Abstract

BACKGROUND: Many alcoholics and heavy drinkers undergo repeated cycles of alcohol abstinence followed by relapse to alcohol drinking; a pattern that contributes to escalated alcohol intake over time. In rodents, alcohol drinking that is interspersed with periods of alcohol deprivation (imposed abstinence) increases alcohol intake during reaccess to alcohol. This is termed the "alcohol deprivation effect" or "ADE" and is a model of alcohol relapse in humans. We have previously reported that prazosin reduces alcohol drinking during both brief and prolonged treatment in rats selectively bred for alcohol preference ("P" rats). This study explores whether prazosin prevents alcohol "relapse" in P rats, as reflected by a reduced or abolished ADE.
METHODS: Adult male P rats were given 24-hour access to food and water and scheduled access to alcohol (15 and 30% v/v solutions presented concurrently) for 2 h/d. After 5 weeks, rats underwent imposed alcohol deprivation for 2 weeks, followed by alcohol reaccess for 2 weeks, and this pattern was repeated for a total of 3 cycles. Rats were injected with prazosin (0, 0.5, 1.0, or 2.0 mg/kg body weight, intraperitoneally) once a day for the first 5 days of each alcohol reaccess cycle.
RESULTS: Alcohol intake increased on the first day of each alcohol reaccess cycle, demonstrating the formation of an ADE. The ADE was short-lived, lasting only 1 day, during each of the 3 cycles. Prazosin, in all doses tested, prevented the expression of an ADE in all 3 alcohol reaccess cycles.
CONCLUSIONS: Prazosin decreases alcohol intake in P rats even in a situation that would be expected to increase alcohol drinking, namely following periods of alcohol deprivation. This suggests that prazosin may be effective in reducing alcohol relapse that often occurs during attempts to achieve permanent alcohol abstinence in treatment-seeking alcoholics and heavy drinkers.
Copyright © 2015 by the Research Society on Alcoholism.

Entities:  

Keywords:  Alcohol Deprivation Effect; Alcohol Preferring Rats; Alcohol Relapse; Prazosin

Mesh:

Substances:

Year:  2015        PMID: 26207767      PMCID: PMC4515780          DOI: 10.1111/acer.12789

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  53 in total

1.  Withdrawal symptoms in a long-term model of voluntary alcohol drinking in Wistar rats.

Authors:  S M Hölter; A C Linthorst; J M Reul; R Spanagel
Journal:  Pharmacol Biochem Behav       Date:  2000-05       Impact factor: 3.533

2.  Combining naltrexone and prazosin in a single oral medication decreases alcohol drinking more effectively than does either drug alone.

Authors:  Janice C Froehlich; Brett J Hausauer; Dennis D Rasmussen
Journal:  Alcohol Clin Exp Res       Date:  2013-07-22       Impact factor: 3.455

3.  What aspects of human alcohol use disorders can be modeled using selectively bred rat lines?

Authors:  J C Froehlich
Journal:  Subst Use Misuse       Date:  2010-09       Impact factor: 2.164

4.  Multiple previous detoxifications are associated with less responsive treatment and heavier drinking during an index outpatient detoxification.

Authors:  R Malcolm; J S Roberts; W Wang; H Myrick; R F Anton
Journal:  Alcohol       Date:  2000-11       Impact factor: 2.405

5.  Chronic daily ethanol and withdrawal: 2. Behavioral changes during prolonged abstinence.

Authors:  D D Rasmussen; D R Mitton; J Green; S Puchalski
Journal:  Alcohol Clin Exp Res       Date:  2001-07       Impact factor: 3.455

6.  The expression of an alcohol deprivation effect in the high-alcohol-drinking replicate rat lines is dependent on repeated deprivations.

Authors:  Z A Rodd-Henricks; D L McKinzie; J M Murphy; W J McBride; L Lumeng; T K Li
Journal:  Alcohol Clin Exp Res       Date:  2000-06       Impact factor: 3.455

7.  Long and short alcohol deprivation: effects on AA and P alcohol-preferring rats.

Authors:  J D Sinclair; T K Li
Journal:  Alcohol       Date:  1989 Nov-Dec       Impact factor: 2.405

8.  Combining the α1 -adrenergic receptor antagonist, prazosin, with the β-adrenergic receptor antagonist, propranolol, reduces alcohol drinking more effectively than either drug alone.

Authors:  Dennis D Rasmussen; Lauren E Beckwith; Carrie L Kincaid; Janice C Froehlich
Journal:  Alcohol Clin Exp Res       Date:  2014-05-30       Impact factor: 3.455

9.  Prazosin reduces alcohol drinking throughout prolonged treatment and blocks the initiation of drinking in rats selectively bred for high alcohol intake.

Authors:  Janice C Froehlich; Brett J Hausauer; David L Federoff; Stephen M Fischer; Dennis D Rasmussen
Journal:  Alcohol Clin Exp Res       Date:  2013-06-03       Impact factor: 3.455

10.  A trial of prazosin for combat trauma PTSD with nightmares in active-duty soldiers returned from Iraq and Afghanistan.

Authors:  Murray A Raskind; Kris Peterson; Tammy Williams; David J Hoff; Kimberly Hart; Hollie Holmes; Dallas Homas; Jeffrey Hill; Colin Daniels; Jess Calohan; Steven P Millard; Kirsten Rohde; James O'Connell; Denise Pritzl; Kevin Feiszli; Eric C Petrie; Christopher Gross; Cynthia L Mayer; Michael C Freed; Charles Engel; Elaine R Peskind
Journal:  Am J Psychiatry       Date:  2013-09       Impact factor: 18.112

View more
  21 in total

1.  Evaluation of the effect of doxasozin and zonisamide on voluntary ethanol intake in mice that experienced chronic intermittent ethanol exposure and stress.

Authors:  Marcelo F Lopez; Sarah E Reasons; Benjamin A Carper; Tracy L Nolen; Rick L Williams; Howard C Becker
Journal:  Alcohol       Date:  2020-07-24       Impact factor: 2.405

2.  Varenicline Reduces Alcohol Intake During Repeated Cycles of Alcohol Reaccess Following Deprivation in Alcohol-Preferring (P) Rats.

Authors:  Janice C Froehlich; Emily R Nicholson; Julian E Dilley; Nick J Filosa; Logan C Rademacher; Teal N Smith
Journal:  Alcohol Clin Exp Res       Date:  2017-07-10       Impact factor: 3.455

Review 3.  A Genetic Animal Model of Alcoholism for Screening Medications to Treat Addiction.

Authors:  R L Bell; S Hauser; Z A Rodd; T Liang; Y Sari; J McClintick; S Rahman; E A Engleman
Journal:  Int Rev Neurobiol       Date:  2016-03-21       Impact factor: 3.230

4.  Combining Varenicline (Chantix) with Naltrexone Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone in a Rodent Model of Alcoholism.

Authors:  Janice C Froehlich; Stephen M Fischer; Julian E Dilley; Emily R Nicholson; Teal N Smith; Nick J Filosa; Logan C Rademacher
Journal:  Alcohol Clin Exp Res       Date:  2016-07-29       Impact factor: 3.455

Review 5.  Rat animal models for screening medications to treat alcohol use disorders.

Authors:  Richard L Bell; Sheketha R Hauser; Tiebing Liang; Youssef Sari; Antoniette Maldonado-Devincci; Zachary A Rodd
Journal:  Neuropharmacology       Date:  2017-02-16       Impact factor: 5.250

Review 6.  The Corticotropin Releasing Factor Receptor 1 in Alcohol Use Disorder: Still a Valid Drug Target?

Authors:  Matthew B Pomrenze; Tracy L Fetterly; Danny G Winder; Robert O Messing
Journal:  Alcohol Clin Exp Res       Date:  2017-10-25       Impact factor: 3.455

7.  Prazosin Prevents Increased Anxiety Behavior That Occurs in Response to Stress During Alcohol Deprivations.

Authors:  Dennis D Rasmussen; Carrie L Kincaid; Janice C Froehlich
Journal:  Alcohol Alcohol       Date:  2016-10-26       Impact factor: 2.826

8.  Co-Administration of Low-Dose Naltrexone and Bupropion Reduces Alcohol Drinking in Alcohol-Preferring (P) Rats.

Authors:  Emily R Nicholson; Julian E Dilley; Janice C Froehlich
Journal:  Alcohol Clin Exp Res       Date:  2018-01-22       Impact factor: 3.455

Review 9.  Noradrenergic targets for the treatment of alcohol use disorder.

Authors:  Carolina L Haass-Koffler; Robert M Swift; Lorenzo Leggio
Journal:  Psychopharmacology (Berl)       Date:  2018-02-20       Impact factor: 4.530

Review 10.  Influence of stress associated with chronic alcohol exposure on drinking.

Authors:  Howard C Becker
Journal:  Neuropharmacology       Date:  2017-04-19       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.